Overview

Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Status:
Active, not recruiting

Trial end date:
2023-04-03

Target enrollment:

Participant gender:

Summary

An Open-label Extension Study in Patients 65 Years or Older with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (Ibrutinib versus Chlorambucil)

Phase:

Phase 3

Details

Lead Sponsor:

Pharmacyclics LLC.

Collaborator:

Janssen Research & Development, LLC

Treatments:

Chlorambucil